Evidence map›Paper›PMID 35235558›Full record

ArticlePLoS computational biology2022

Missense variants in human ACE2 strongly affect binding to SARS-CoV-2 Spike providing a mechanism for ACE2 mediated genetic risk in Covid-19: A case study in affinity predictions of interface variants.

Stuart A MacGowan, Michael I Barton, Mikhail Kutuzov, Omer Dushek, P Anton van der Merwe, Geoffrey J Barton

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Highly pathogenic coronaviruses and the kidney.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  7. Article
  8. Article
  9. Human genetic basis of severe or critical illness in COVID-19.Frontiers in cellular and infection microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Stuart A MacGowanDivision of Computational Biology, School of Life Sciences, University of Dundee, Dow Street, Dundee, Scotland, United Kingdom.ORCID 0000-0003-4233-5071
Michael I BartonSir William Dunn School of Pathology, South Parks Road, University of Oxford, Oxford, Oxfordshire, United Kingdom.ORCID 0000-0002-9263-6481
Mikhail KutuzovSir William Dunn School of Pathology, South Parks Road, University of Oxford, Oxford, Oxfordshire, United Kingdom.ORCID 0000-0003-3386-4350
Omer DushekSir William Dunn School of Pathology, South Parks Road, University of Oxford, Oxford, Oxfordshire, United Kingdom.ORCID 0000-0001-5847-5226
P Anton van der MerweSir William Dunn School of Pathology, South Parks Road, University of Oxford, Oxford, Oxfordshire, United Kingdom.
Geoffrey J BartonDivision of Computational Biology, School of Life Sciences, University of Dundee, Dow Street, Dundee, Scotland, United Kingdom.ORCID 0000-0002-9014-5355
University of Oxford · GBUniversity of Dundee · GB

Funding

Biotechnology and Biological Sciences Research Council BB/G022682/1Biotechnology and Biological Sciences Research Council BB/J019364/1Biotechnology and Biological Sciences Research Council BB/L020742/1Biotechnology and Biological Sciences Research Council BB/R014752/1Wellcome TrustWellcome Trust 101651Wellcome Trust 207537
6 · The paper itself

Abstract

SARS-CoV-2 Spike (Spike) binds to human angiotensin-converting enzyme 2 (ACE2) and the strength of this interaction could influence parameters relating to virulence. To explore whether population variants in ACE2 influence Spike binding and hence infection, we selected 10 ACE2 variants based on affinity predictions and prevalence in gnomAD and measured their affinities and kinetics for Spike receptor binding domain through surface plasmon resonance (SPR) at 37°C. We discovered variants that reduce and enhance binding, including three ACE2 variants that strongly inhibited (p.Glu37Lys, ΔΔG = -1.33 ± 0.15 kcal mol-1 and p.Gly352Val, predicted ΔΔG = -1.17 kcal mol-1) or abolished (p.Asp355Asn) binding. We also identified two variants with distinct population distributions that enhanced affinity for Spike. ACE2 p.Ser19Pro (ΔΔG = 0.59 ± 0.08 kcal mol-1) is predominant in the gnomAD African cohort (AF = 0.003) whilst p.Lys26Arg (ΔΔG = 0.26 ± 0.09 kcal mol-1) is predominant in the Ashkenazi Jewish (AF = 0.01) and European non-Finnish (AF = 0.006) cohorts. We compared ACE2 variant affinities to published SARS-CoV-2 pseudotype infectivity data and confirmed that ACE2 variants with reduced affinity for Spike can protect cells from infection. The effect of variants with enhanced Spike affinity remains unclear, but we propose a mechanism whereby these alleles could cause greater viral spreading across tissues and cell types, as is consistent with emerging understanding regarding the interplay between receptor affinity and cell-surface abundance. Finally, we compared mCSM-PPI2 ΔΔG predictions against our SPR data to assess the utility of predictions in this system. We found that predictions of decreased binding were well-correlated with experiment and could be improved by calibration, but disappointingly, predictions of highly enhanced binding were unreliable. Recalibrated predictions for all possible ACE2 missense variants at the Spike interface were calculated and used to estimate the overall burden of ACE2 variants on Covid-19.

Indexed as

Mutation, MissenseAngiotensin-Converting Enzyme 2COVID-19Genetic Predisposition to DiseaseHumansProtein BindingSpike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID35235558
PMCPMC8920257
OpenAlexW4214847247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.